Subtle Medical’s AI-Based Synthetic Imaging Software Gains the US FDA’s Clearance
Shots:
- The US FDA grants clearance to the company’s SubtleSYNTH software that creates synthetic STIR images (SynthSTIR’s) from T1 & T2 weighted contrasts by utilizing deep learning (DL) in zero acquisition time that are interchangeable with conventional STIR images
- Software was verified for spinal use in a demographically broader study published in AJNR. The company now anticipates the expansion of technology to Brain & MSK imaging
- In addition, Subtle received a $2.3M NIH SBIR grant in 2023 to expand SubtleSYNTH technology, aiming to improve quality and speed of MRI imaging with their advanced solutions
Ref: Subtle Medical | Image: Subtle Medical
Related News: Abbott Launches Upgraded Version of NeuroSphere myPath Digital Health App to Boost Connected Care Technology for Chronic Pain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
